<DOC>
	<DOC>NCT00878189</DOC>
	<brief_summary>This is a phase 1, dose escalating study to determine the safety of PF-03084014 in patients with advanced cancer and leukemia</brief_summary>
	<brief_title>A Trial In Patients With Advanced Cancer And Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms by Histologic Type</mesh_term>
	<criteria>Patients with advanced cancer that is resistant to standard therapy or for which no standard therapy is available Patients with acute T cell leukemia/lymphoblastic lymphoma that is resistant to standard therapy or for which no standard therapy is available Men and women &gt;16 years old Prior treatment with a gamma secretase inhibitor for treatment of cancer Patients taking Tamoxifen Patients with active graft versus host disease Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness Patients who are pregnant or breast feeding Patients with clinical evidence of central nervous system disease</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Phase 1 dose escalation study in advanced solid tumor malignancy and leukemia</keyword>
</DOC>